Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Study of ANAVEX2-73 in Patients With Rett Syndrome

Next Previous
X
Search
Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Study of ANAVEX2-73 in Patients With Rett Syndrome

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Blarcamesine (Primary)
  • Indications Rett syndrome
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms AVATAR
  • Sponsors Anavex Life Sciences

    • Most Recent Events

    • 20 Dec 2023 First entire clinical gene pathway data from the ANAVEX2-73-RS-002 AVATAR Rett syndrome trial published in the Anavex Life Sciences Media Release
    • 04 Feb 2022 According to an Anavex Life Sciences media release, based on the results from the AVATAR study and a phase II study ANAVEX2-73-RS-001, the company is planning to meet with the FDA to discuss the approval pathway.
    • 01 Feb 2022 According to an Anavex Media Release, company will host a webcast today to discuss the top-line results from this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top